Women's Health

Is BMI or body fat a better estimate of obesity?; spoiler: older women do drink ETOH; USPSTF vs ACC/AHA; plus no more opioids for LBP and a primer on migraine meds.

The US FDA approved norgestrel as the first daily oral contraceptive to be available over the counter, without a prescription.

Binge drinking among women going through menopause has been on the rise, research indicates, making clinical inquiry in this population particularly important.

The greatest increase over the 10 years was seen in deaths among American Indian and Alaska Native women, according to Institute for Health Metrics and Evaluation data.

Your daily dose of clinical news you may have missed.

Higher scores on a healthy lifestyle index were associated with significantly reduced risk of incident CVD among women aged 50-79 years with BMI between 18.5 and 25.0.

Your daily dose of clinical news you may have missed.

ENDO 2023. Women with PCOS face an increased risk of mortality, particularly death due to cardiovascular disease and diabetes, compared with those without PCOS.

Ozempic impact on patients, clinicians; bempedoic acid comparable to statins; hypertension risk upped with oral estrogen HT; and 2 more quotes of note.

Your daily dose of clinical news you may have missed.

Oral estrogen hormone therapy was more likely to result in incident hypertension than transdermal or vaginal formulations in this large prospective population-based study.

Menstrual migraine is often described as more disabling than non-menstrual migraine. Get an overview and test your knowledge, here.

Your daily dose of clinical news you may have missed.

A nationally recognized obesity expert discusses mental health in women with obesity.

The findings contradict published clinical guidelines that warn against use of estrogen-containing birth control by women who have migraine with aura.

Your daily dose of clinical news you may have missed.

Women's Health Week (May 14-20, 2023) is an ideal opportunity to review the top research, policy shifts, and potential drug approvals that affect your patient panel.

Fezolinetant is the first NK3 receptor antagonist approved by the FDA for treatment of moderate-to-severe vasomotor symptoms due to menopause.

Your daily dose of clinical news you may have missed.

Opill, a progestin-only oral contraceptive, if approved by the FDA, would be the first an only form of birth control in the US available without a physician's prescription.

Denosumab reduced RR of fracture vs alendronate across fracture types, eg, by 36% for hip fracture, by 43% for nonvertebral fractures, and by 30% for vertebral fractures.

The lower recommended starting age for screening reflects rising cancer diagnoses among younger women and persistently high mortality rates among Black women.

Results of a Mendelian randomization study showed earlier first birth, higher number of live births, and earlier menarche are all associated with increased CVD.

Sex-based disparities found in high-profile clinical trials presented at 3 key cardiology scientific meetings underscore the lack of progress made toward equitable inclusion in research.

Tirzepatide delivers 15.7% weight loss in adults with obesity; remote intervention increases cancer screening in women; women at greater post-MI risk vs men; plus 2 more updates of note.